Great post fouremm!

Thanks for posting the article. There are plenty of deals being made. Why not RVX?

As the article stated:

"These deals haven’t come cheap, however, with premiums on biopharma acquisitions surpassing 100% many times in recent years. Such high prices have been due, at least in part, to the fact that biotechs were able to secure large amounts of funding from private investors and the public markets, in turn forcing potential buyers to offer up more money to lock down deals."

 Apabetalone needs BOM2 financing and approval to garner the deal that RVX is looking for. Seemingly it all boils down to trial $$$s.